This Phase II study is a clinical study exploring the efficacy and safety of BL-M14D1 in combination with Atezolizumab in patients with extensive-stage small cell lung cancer.
Voluntarily sign the informed consent form and comply with the protocol requirements;
No gender restriction;
Age: ≥18 years;
Expected survival time ≥3 months;
Use of chemotherapy, biological therapy, immunotherapy, etc., within 4 weeks or 5 half-lives before the first dose;
Previous treatment with ADC drugs using topoisomerase I inhibitors as toxins;
Small cell carcinoma with non-small cell carcinoma components indicated by pathology must be excluded;
Use of immunomodulatory drugs within 2 weeks before the first dose of the study;
Sichuan Baili Pharmaceutical Co., Ltd.
Lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Collaborator